Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner.

Journal of thrombosis and haemostasis : JTH·2026

Same author

The insulin-like peptides Dilp2 and Dilp6 exhibit divergent responses to dietary sugar and protein in <i>Drosophila</i> larvae.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Optogenetic restoration of high-sensitivity vision using ChRmine- and ChroME-based channelrhodopsins.

Scientific reports·2025

Same author

Truncated complement factor H Y402 gene therapy rescues C3 glomerulonephritis.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Dopamine D1 receptor activation in the striatum is sufficient to drive reinforcement of anteceding cortical patterns.

Neuron·2025

Same author

Synchronizing Drosophila larvae with the salivary gland reporter Sgs3-GFP for discovery of phenotypes in the late third instar stage.

Developmental biology·2024

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis.

Lindsey A Chew^1,2, Daniel Grigsby³, C Garren Hester¹

¹Department of Ophthalmology, Duke Eye Center, Duke University Medical Center, Durham, NC 27710.

Biorxiv : the Preprint Server for Biology

|September 30, 2024

Summary

Adeno-associated virus delivery of truncated complement factor H (tCFH) effectively reversed C3 glomerulonephritis in mice. This gene therapy approach shows promise for treating C3G and age-related macular degeneration.

Keywords:

C3 glomerulonephritis C3 glomerulopathy age-related macular degeneration complement factor H complement regulation gene replacement gene therapy

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Related Experiment Videos

Last Updated: Jun 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Area of Science:

Ophthalmology
Nephrology
Gene Therapy

Background:

Age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) share complement dysregulation pathways.
Current therapies for C3G are limited, and previous attempts using exogenous complement factor H (CFH) faced immune rejection.
C3G is characterized by complement alternative pathway dysregulation.

Purpose of the Study:

To investigate adeno-associated virus (AAV)-mediated delivery of truncated CFH (tCFH) for treating C3G.
To assess the efficacy and long-term safety of AAV-tCFH gene therapy in a mouse model.
To explore AAV-tCFH as a potential therapy for both C3G and AMD.

Main Methods:

Utilized a Cfh-/- mouse model of C3G.
Administered various adeno-associated virus (AAV) vectors encoding truncated complement factor H (tCFH).
Monitored complement pathway inhibition, disease reversal, and immune response.

Main Results:

Long-term AAV-mediated delivery of tCFH successfully inhibited the complement alternative pathway.
Reversal of C3G was achieved without evidence of immune rejection.
Different AAV vectors demonstrated varying levels of efficiency and efficacy.

Conclusions:

AAV-mediated tCFH gene therapy offers a promising strategy for C3G treatment, overcoming limitations of previous approaches.
This study provides proof of concept for AAV-tCFH gene augmentation therapy for AMD.
The findings support the development of novel gene therapies targeting complement dysregulation in both C3G and AMD patients.